Allergan PLC (AGN) Shares Sold by Fishman Jay A Ltd. MI
Fishman Jay A Ltd. MI reduced its position in Allergan PLC (NYSE:AGN) by 5.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,598 shares of the company’s stock after selling 5,765 shares during the period. Allergan PLC comprises 5.7% of Fishman Jay A Ltd. MI’s portfolio, making the stock its 4th largest position. Fishman Jay A Ltd. MI’s holdings in Allergan PLC were worth $23,169,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of AGN. Vanguard Group Inc. boosted its position in shares of Allergan PLC by 1.9% in the second quarter. Vanguard Group Inc. now owns 24,362,503 shares of the company’s stock valued at $5,629,931,000 after buying an additional 445,456 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Allergan PLC by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 4,390,394 shares of the company’s stock valued at $1,011,151,000 after buying an additional 329,024 shares in the last quarter. Jackson Square Partners LLC boosted its position in shares of Allergan PLC by 5.7% in the second quarter. Jackson Square Partners LLC now owns 3,840,160 shares of the company’s stock valued at $1,004,656,000 after buying an additional 205,701 shares in the last quarter. General Electric Co. boosted its position in shares of Allergan PLC by 13.7% in the second quarter. General Electric Co. now owns 2,676,658 shares of the company’s stock valued at $618,549,000 after buying an additional 322,108 shares in the last quarter. Finally, Veritas Asset Management LLP acquired a new position in shares of Allergan PLC during the second quarter valued at $492,177,000. 86.89% of the stock is owned by institutional investors and hedge funds.
Shares of Allergan PLC (NYSE:AGN) traded down 0.54% during midday trading on Monday, hitting $191.19. 2,211,586 shares of the stock traded hands. The company has a market cap of $71.71 billion, a price-to-earnings ratio of 5.36 and a beta of 1.08. Allergan PLC has a 52-week low of $184.50 and a 52-week high of $322.68. The stock has a 50-day moving average of $212.72 and a 200-day moving average of $233.35.
Allergan PLC (NYSE:AGN) last issued its earnings results on Wednesday, November 2nd. The company reported $3.32 EPS for the quarter, missing analysts’ consensus estimates of $3.65 by $0.33. Allergan PLC had a return on equity of 7.26% and a net margin of 93.74%. The firm had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.73 billion. During the same period last year, the firm earned $3.48 earnings per share. Allergan PLC’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities analysts predict that Allergan PLC will post $13.37 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 28th. Shareholders of record on Tuesday, February 28th will be paid a dividend of $0.70 per share. This is an increase from Allergan PLC’s previous quarterly dividend of $0.05. This represents a $2.80 dividend on an annualized basis and a yield of 1.46%.
TRADEMARK VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/28/allergan-plc-agn-shares-sold-by-fishman-jay-a-ltd-mi.html.
Several research analysts have recently weighed in on AGN shares. William Blair reiterated a “market perform” rating on shares of Allergan PLC in a research note on Monday, November 21st. Goldman Sachs Group Inc. restated a “buy” rating on shares of Allergan PLC in a research note on Monday, September 12th. JPMorgan Chase & Co. set a $325.00 target price on shares of Allergan PLC and gave the company a “buy” rating in a research note on Friday, August 5th. Barclays PLC restated an “equal weight” rating and set a $250.00 target price on shares of Allergan PLC in a research note on Monday, October 31st. Finally, Credit Suisse Group AG restated an “outperform” rating and set a $329.00 target price on shares of Allergan PLC in a research note on Thursday, November 3rd. Seven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $289.11.
In other news, CEO Brent L. Saunders bought 5,250 shares of Allergan PLC stock in a transaction on Monday, November 21st. The shares were bought at an average cost of $189.13 per share, with a total value of $992,932.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Maria Teresa Hilado bought 1,422 shares of Allergan PLC stock in a transaction on Friday, November 11th. The shares were purchased at an average cost of $210.64 per share, for a total transaction of $299,530.08. Following the completion of the purchase, the chief financial officer now directly owns 12,659 shares of the company’s stock, valued at $2,666,491.76. The disclosure for this purchase can be found here. Company insiders own 0.27% of the company’s stock.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.